---
document_datetime: 2025-12-02 05:44:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vafseo.html
document_name: vafseo.html
version: success
processing_time: 0.1047976
conversion_datetime: 2025-12-25 06:54:54.132034
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vafseo

[RSS](/en/individual-human-medicine.xml/67668)

##### Authorised

This medicine is authorised for use in the European Union

vadadustat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vafseo](#news-on)
- [More information on Vafseo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vafseo is a medicine used to treat the symptoms of anaemia (low red blood cell counts) caused by chronic kidney disease (long-term, progressive decrease in the ability of the kidneys to work properly) in adult patients on dialysis (a technique for removing unwanted substances and excess fluid from the blood when the kidneys do not work well enough).

Vafseo contains the active substance vadadustat.

Expand section

Collapse section

## How is Vafseo used?

Vafseo can only be obtained with a prescription, and treatment should be started by a doctor experienced in the management of anaemia. It is available as tablets to be taken once a day.

For more information about using Vafseo, see the package leaflet or contact your doctor or pharmacist.

## How does Vafseo work?

Patients with chronic kidney disease may not produce enough erythropoietin, a hormone needed to stimulate the production of red blood cells. The active substance in Vafseo, vadadustat, acts on an enzyme called hypoxia-inducible factor prolyl hydroxylase (HIF-PH). This stimulates the natural response that normally occurs when oxygen levels are low, including the production of erythropoietin and red blood cells.

## What benefits of Vafseo have been shown in studies?

Two main studies involving nearly 4,000 patients with anaemia caused by chronic kidney disease who were on dialysis showed that Vafseo was as effective as darbepoetin alfa (another medicine for treating anaemia) at increasing blood levels of haemoglobin.

## What are the risks associated with Vafseo?

For the full list of side effects and restrictions with Vafseo, see the package leaflet.

The most common side effects with Vafseo (which may affect more than 1 in 10 people) include thromboembolic events (problems due to the formation of blood clots in the blood vessels), diarrhoea and hypertension (high blood pressure).

## Why is Vafseo authorised in the EU?

Vafseo was shown to be as effective as the comparator medicine darbepoetin alfa at treating anaemia in patients with chronic kidney disease who were on dialysis. With regard to safety, the risk of thromboembolic events in patients treated with Vafseo is addressed with warnings in the prescribing information. The European Medicines Agency therefore decided that Vafseo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vafseo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vafseo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vafseo are continuously monitored. Suspected side effects reported with Vafseo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vafseo

Vafseo received a marketing authorisation valid throughout the EU on 24 April 2023.

Further information on Vafseo can be found on the Agency's website: [ema.europa.eu/medicines/human/EPAR/vafseo](/en/medicines/human/EPAR/vafseo)

This overview was last updated in 04-2023.

Vafseo: EPAR - Medicine overview

Reference Number: EMA/100938/2023

English (EN) (116.32 KB - PDF)

**First published:** 31/05/2023

[View](/en/documents/overview/vafseo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-953)

български (BG) (136.5 KB - PDF)

**First published:**

31/05/2023

[View](/bg/documents/overview/vafseo-epar-medicine-overview_bg.pdf)

español (ES) (116.1 KB - PDF)

**First published:**

31/05/2023

[View](/es/documents/overview/vafseo-epar-medicine-overview_es.pdf)

čeština (CS) (134.88 KB - PDF)

**First published:**

31/05/2023

[View](/cs/documents/overview/vafseo-epar-medicine-overview_cs.pdf)

dansk (DA) (115.67 KB - PDF)

**First published:**

31/05/2023

[View](/da/documents/overview/vafseo-epar-medicine-overview_da.pdf)

Deutsch (DE) (117.7 KB - PDF)

**First published:**

31/05/2023

[View](/de/documents/overview/vafseo-epar-medicine-overview_de.pdf)

eesti keel (ET) (105.32 KB - PDF)

**First published:**

31/05/2023

[View](/et/documents/overview/vafseo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (134.89 KB - PDF)

**First published:**

31/05/2023

[View](/el/documents/overview/vafseo-epar-medicine-overview_el.pdf)

français (FR) (117.06 KB - PDF)

**First published:**

31/05/2023

[View](/fr/documents/overview/vafseo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (137.24 KB - PDF)

**First published:**

31/05/2023

[View](/hr/documents/overview/vafseo-epar-medicine-overview_hr.pdf)

italiano (IT) (115.14 KB - PDF)

**First published:**

31/05/2023

[View](/it/documents/overview/vafseo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (143.36 KB - PDF)

**First published:**

31/05/2023

[View](/lv/documents/overview/vafseo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (136.29 KB - PDF)

**First published:**

31/05/2023

[View](/lt/documents/overview/vafseo-epar-medicine-overview_lt.pdf)

magyar (HU) (135.8 KB - PDF)

**First published:**

31/05/2023

[View](/hu/documents/overview/vafseo-epar-medicine-overview_hu.pdf)

Malti (MT) (137.08 KB - PDF)

**First published:**

31/05/2023

[View](/mt/documents/overview/vafseo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (116.12 KB - PDF)

**First published:**

31/05/2023

[View](/nl/documents/overview/vafseo-epar-medicine-overview_nl.pdf)

polski (PL) (137.38 KB - PDF)

**First published:**

31/05/2023

[View](/pl/documents/overview/vafseo-epar-medicine-overview_pl.pdf)

português (PT) (116.72 KB - PDF)

**First published:**

31/05/2023

[View](/pt/documents/overview/vafseo-epar-medicine-overview_pt.pdf)

română (RO) (132.99 KB - PDF)

**First published:**

31/05/2023

[View](/ro/documents/overview/vafseo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (134.38 KB - PDF)

**First published:**

31/05/2023

[View](/sk/documents/overview/vafseo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (133.63 KB - PDF)

**First published:**

31/05/2023

[View](/sl/documents/overview/vafseo-epar-medicine-overview_sl.pdf)

Suomi (FI) (114.59 KB - PDF)

**First published:**

31/05/2023

[View](/fi/documents/overview/vafseo-epar-medicine-overview_fi.pdf)

svenska (SV) (114.52 KB - PDF)

**First published:**

31/05/2023

[View](/sv/documents/overview/vafseo-epar-medicine-overview_sv.pdf)

Vafseo: EPAR - Risk-management-plan

English (EN) (756.02 KB - PDF)

**First published:** 31/05/2023

[View](/en/documents/rmp/vafseo-epar-risk-management-plan_en.pdf)

## Product information

Vafseo: EPAR - Product Information

English (EN) (550.32 KB - PDF)

**First published:** 31/05/2023

**Last updated:** 27/03/2025

[View](/en/documents/product-information/vafseo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-390)

български (BG) (864.39 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/bg/documents/product-information/vafseo-epar-product-information_bg.pdf)

español (ES) (545.6 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/es/documents/product-information/vafseo-epar-product-information_es.pdf)

čeština (CS) (854.85 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/cs/documents/product-information/vafseo-epar-product-information_cs.pdf)

dansk (DA) (748.82 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/da/documents/product-information/vafseo-epar-product-information_da.pdf)

Deutsch (DE) (791.39 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/de/documents/product-information/vafseo-epar-product-information_de.pdf)

eesti keel (ET) (562.89 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/et/documents/product-information/vafseo-epar-product-information_et.pdf)

ελληνικά (EL) (632.31 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/el/documents/product-information/vafseo-epar-product-information_el.pdf)

français (FR) (766.87 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/fr/documents/product-information/vafseo-epar-product-information_fr.pdf)

hrvatski (HR) (773.65 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/hr/documents/product-information/vafseo-epar-product-information_hr.pdf)

íslenska (IS) (627.46 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/is/documents/product-information/vafseo-epar-product-information_is.pdf)

italiano (IT) (591.97 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/it/documents/product-information/vafseo-epar-product-information_it.pdf)

latviešu valoda (LV) (782.18 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/lv/documents/product-information/vafseo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (595.69 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/lt/documents/product-information/vafseo-epar-product-information_lt.pdf)

magyar (HU) (638.53 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/hu/documents/product-information/vafseo-epar-product-information_hu.pdf)

Malti (MT) (621.48 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/mt/documents/product-information/vafseo-epar-product-information_mt.pdf)

Nederlands (NL) (559.53 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/nl/documents/product-information/vafseo-epar-product-information_nl.pdf)

norsk (NO) (782.07 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/no/documents/product-information/vafseo-epar-product-information_no.pdf)

polski (PL) (652.91 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/pl/documents/product-information/vafseo-epar-product-information_pl.pdf)

português (PT) (765.81 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/pt/documents/product-information/vafseo-epar-product-information_pt.pdf)

română (RO) (687.48 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/ro/documents/product-information/vafseo-epar-product-information_ro.pdf)

slovenčina (SK) (813.04 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/sk/documents/product-information/vafseo-epar-product-information_sk.pdf)

slovenščina (SL) (776.4 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/sl/documents/product-information/vafseo-epar-product-information_sl.pdf)

Suomi (FI) (748.65 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/fi/documents/product-information/vafseo-epar-product-information_fi.pdf)

svenska (SV) (765.49 KB - PDF)

**First published:**

31/05/2023

**Last updated:**

27/03/2025

[View](/sv/documents/product-information/vafseo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000254042 27/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vafseo: EPAR - All authorised presentations

English (EN) (61.62 KB - PDF)

**First published:** 31/05/2023

[View](/en/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-960)

български (BG) (71.23 KB - PDF)

**First published:**

31/05/2023

[View](/bg/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.84 KB - PDF)

**First published:**

31/05/2023

[View](/es/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (42.81 KB - PDF)

**First published:**

31/05/2023

[View](/cs/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (44.25 KB - PDF)

**First published:**

31/05/2023

[View](/da/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (44.46 KB - PDF)

**First published:**

31/05/2023

[View](/de/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (44.21 KB - PDF)

**First published:**

31/05/2023

[View](/et/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (60.01 KB - PDF)

**First published:**

31/05/2023

[View](/el/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_el.pdf)

français (FR) (44.33 KB - PDF)

**First published:**

31/05/2023

[View](/fr/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (59.83 KB - PDF)

**First published:**

31/05/2023

[View](/hr/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (43.92 KB - PDF)

**First published:**

31/05/2023

[View](/is/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (47.73 KB - PDF)

**First published:**

31/05/2023

[View](/it/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.63 KB - PDF)

**First published:**

31/05/2023

[View](/lv/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (64.53 KB - PDF)

**First published:**

31/05/2023

[View](/lt/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (61.25 KB - PDF)

**First published:**

31/05/2023

[View](/hu/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (64.54 KB - PDF)

**First published:**

31/05/2023

[View](/mt/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (47.41 KB - PDF)

**First published:**

31/05/2023

[View](/nl/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.43 KB - PDF)

**First published:**

31/05/2023

[View](/no/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_no.pdf)

polski (PL) (57.17 KB - PDF)

**First published:**

31/05/2023

[View](/pl/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.35 KB - PDF)

**First published:**

31/05/2023

[View](/pt/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_pt.pdf)

română (RO) (55.24 KB - PDF)

**First published:**

31/05/2023

[View](/ro/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (64.16 KB - PDF)

**First published:**

31/05/2023

[View](/sk/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (63.41 KB - PDF)

**First published:**

31/05/2023

[View](/sl/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.6 KB - PDF)

**First published:**

31/05/2023

[View](/fi/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.19 KB - PDF)

**First published:**

31/05/2023

[View](/sv/documents/all-authorised-presentations/vafseo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vafseo Active substance vadadustat International non-proprietary name (INN) or common name vadadustat Therapeutic area (MeSH)

- Renal Insufficiency, Chronic
- Anemia

### Pharmacotherapeutic group

Antianemic preparations

### Therapeutic indication

Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

## Authorisation details

EMA product number EMEA/H/C/005131

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Medice Arzneimittel Pütter GmbH &amp; Co. KG

Medice Arzneimittel Pütter GmbH &amp; Co. KG

Opinion adopted 23/02/2023 Marketing authorisation issued 24/04/2023 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vafseo: EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (140.34 KB - PDF)

**First published:** 27/03/2025

[View](/en/documents/procedural-steps-after/vafseo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vafseo: EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (104.87 KB - PDF)

**First published:** 05/03/2024

**Last updated:** 27/03/2025

[View](/en/documents/procedural-steps-after/vafseo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Vafseo: EPAR - Public assessment report

Adopted

Reference Number: EMA/130457/2023

English (EN) (11.9 MB - PDF)

**First published:** 31/05/2023

[View](/en/documents/assessment-report/vafseo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vafseo

Adopted

Reference Number: EMA/CHMP/64870/2023

English (EN) (128.01 KB - PDF)

**First published:** 24/02/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vafseo_en.pdf)

#### News on Vafseo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-february-2023) 24/02/2023

#### More information on Vafseo

- [EMEA-001944-PIP01-16-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001944-pip01-16-m05)

**This page was last updated on** 27/03/2025

## Share this page

[Back to top](#main-content)